Kracie Pharmaceutical

Kracie Pharmaceutical is a leading Japanese healthcare company specializing in Kampo (traditional Japanese herbal) medicine and over-the-counter (OTC) pharmaceuticals. Originally part of the Kanebo group, the company provides a wide range of products including ethical drugs, proprietary herbal formulations, and consumer health products targeting respiratory, digestive, and dermatological conditions. Kracie is particularly recognized for its extensive lineup of Kampo extract tablets and granules, maintaining a significant market share in Japan's traditional medicine sector. In 2023, the company became a wholly-owned subsidiary of Kao Corporation, integrating its wellness expertise into a broader consumer goods portfolio. The company is committed to modernizing traditional medicine through advanced extraction technologies and rigorous quality control.